Marinomed Biotech AG (WBO:MARI) 3-Year Revenue Growth Rate : 3.10% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Marinomed Biotech AG 3-Year Revenue Growth Rate?

Marinomed Biotech AG's Revenue per Share for the three months ended in Dec. 2023 was €1.33.

During the past 12 months, Marinomed Biotech AG's average Revenue per Share Growth Rate was -19.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Marinomed Biotech AG was 48.40% per year. The lowest was 3.10% per year. And the median was 20.70% per year.

Competitive Comparison of Marinomed Biotech AG's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Marinomed Biotech AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marinomed Biotech AG's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's 3-Year Revenue Growth Rate falls into.

Marinomed Biotech AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Marinomed Biotech AG (WBO:MARI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Marinomed Biotech AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinomed Biotech AG (WBO:MARI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (WBO:MARI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

93Z:Germany

Address

Hovengasse 25, Korneuburg, AUT, 2100

Website

https://www.marinomed.com

Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generates from the virology segment.

Marinomed Biotech AG (WBO:MARI) Headlines

No Headlines